| HOME >> MEDICINE >> TECHNOLOGY |
One patient with IVb cancer, who had failed two prior courses of chemotherapy and a course of radiation was deemed sufficiently healthy to resume chemotherapy undergo surgery after receiving the vaccine and was removed from the trial early for this purpose and currently tumor free.
"This milestone has given us the direction for the continued development Listeria-based vaccines," said Rothman. Further vaccines in development target breast, ovarian and lung cancers. For more information log on to http://www.advaxis.com.
| SOURCE Advaxis, Inc. Copyright©2007 PR Newswire. All rights reserved |